




ACTaccelerator
ACCESS TO COVID-19 TOOLS

Health Systems Connector

Country-level implementation

ACT now, ACT together to accelerate the end of the COVID-19 crisis

Zsuzsanna Jakab,
Muhammad Pate,
Peter Sands



In 2021, HSC's primary objective is to enable integrated delivery and effective deployment of COVID-19 tools

Ensure delivery of...



US\$ **6.3 bn**
worth of **PPE**¹

Support delivery of...



900 mn
diagnostic tests



Existing therapeutics for up to
12 mn severe & critical patients
and **new therapies** for up to
100 mn treatment courses





At least **2 bn**
vaccine doses

Objectives to be verified following country-level need assessment

1. US\$ 2,895 mn for the procurement of PPE in Q1/Q2 2021 and US\$ 3,450 mn for the procurement of PPE in Q3/Q4 2021

HSC aims to shift to a country-level approach



From...

Developing global standards, tools and guidance to prepare for deployment of new tools

HSC work streams partially aligned with SPRP pillars

Limited interaction between HSC and the Pillars

Incomplete visibility of availability and use of COVID-19 tools, incl. PPE

Identifying bottlenecks



To...

Real-time operational support at country level to increase uptake of new tools and support countries in accessing external financing


Full integration with the national preparedness and response plans through incident management teams at country level

Integrated approach to Dx, Tx, and Vx Pillars with regular and frequent touchpoints

Transparency on COVID-19 tools (e.g. procurement, delivery, uptake etc.) at the country level

Addressing bottlenecks at the country level

To achieve this objective, HSC's key priorities for 2021 are



- 1 Fully integrate the work and products of the Pillars with a **strengthened, ongoing COVID-19 response**
- 2 Rapidly identify and address **country-specific health systems bottlenecks** to ensure readiness and rapid scale up and delivery of COVID-19 tools
- 3 Accelerate **availability and use of PPE** as a crucial tool for protecting health workers and ensuring the resilience of the health system
- 4 Manage linkages and synergies with complementary activities for the **delivery of essential health services and strengthening of health systems**

Deep dive: HSC Key Priorities 1 and 2

Integrate with response and rapidly address bottlenecks at country level

Activities

Critical needs and gaps monitored and addressed through updated preparedness and response plans

Continuous needs assessment for COVID-19 tools at country level

Continuous identification of health system gaps/bottlenecks

Addressing of gaps/bottlenecks to increase uptake of COVID-19 tools at the country level

Integrated country plans for roll-out of COVID-19 tools

Allocation and prioritization of COVID-19 tools, incl. PPEs based on continuous need assessment

Supply chains

Strengthening of in-country supply chains

Community engagement

Enablement of community-led response through community engagement at the national and global level

Private sector engagement

Data for decision-making (M&E), incl. dashboard

Integrated data management to allow evidence-based global strategic decision-making

Real-time information (e.g. COVID-19 commodities dashboard)

Deep dive – HSC Key Priority 3: Rethinking PPE

Focus areas	Key activities
Innovation, evidence and development	<p>Identification of user needs not being met by currently available PPE including acceptability, comfort and compatibility</p> <hr/> <p>Stimulation of research & innovation targeting unmet needs expressed by users, as well as affordability and protection performance</p> <hr/> <p>Reinforcement of scientific evidence to guide innovation priorities and corresponding specifications and standards</p>
Manufacturing, procurement and supply	<p>Determination of how to build and sustain surge capacity, while improving equitable access and resilience</p> <hr/> <p>Evaluation of lessons learnt on PPE procurement and buyer behaviors, and suggestion of potential best practices</p> <hr/> <p>Design of processes to ensure quality assurance, and benchmarking / harmonization of standards</p>
Deployment, utilization and disposal	<p>Ensuring of timely training and guidance for health care workers and communities based on the latest evidence</p> <hr/> <p>Analysis of pain points related to usage and deployment, including gap between normative guidance and real usage in countries</p> <hr/> <p>Support for safe disposal / reprocessing of PPE</p>
Investment case	<p>Evaluation of infections averted/lives saved per \$ spent on PPE and cost-effectiveness compared to other interventions</p>

Deep dive: HSC Key Priority 4

Complementary activities

Activities

Coordination with broader COVID-19 response

Coordination with the ongoing efforts to support a comprehensive COVID-19 response and address the secondary health crisis

Health systems strengthening for UHC

Coordination with the broader complementary health systems work, including the UHC2030 and the UHC partnership

Health systems protecting

Increase of capacity of existing health systems and prevention of disruption, draining or redirecting of limited resources to the pandemic response

HSC priority actions to drive country impact

Use existing coordination mechanisms and platforms

2. Review & prioritize country response plans to identify critical gaps based on national context

1. Develop evidence-based guidelines & knowledge platforms to address critical health system gaps



3. Ensure uptake & alignment of country level financial instruments to address critical gaps and accelerate implementation of new tools

Support countries in accessing available domestic & bilateral financing




4. Monitor access to and uptake of new tools and share lessons via HSC common knowledge platform

Countries can leverage a number of funding sources

COVAX AMC

Cumulative COVAX AMC pledges, cash and signed donor agreements

AMC funding pledged and received (cumulative and overlapping, not stacked) and number of doses locked in as of end of March 2021



C19RM

C19RM OVERVIEW | PRINCIPLES & ELIGIBILITY

Overview

- **Diligence** through a robust end-to-end process that is streamlined to collect required information up-front.
- **Speed and agility** appropriate for an emergency response.
- **Quality** to strengthen the COVID-19 response through expanded partner engagement.

Eligibility Applicants

- All countries and regional/multicountry recipients that are currently receiving funding from the Global Fund.

This includes countries receiving funding during the 2017-2019 and 2020-2022 allocation periods, including through the approach for non-eligible countries in crisis.

Eligible Investments

- COVID-19 control and containment (PPE, Dx, therapeutics)
- COVID-19-related risk mitigation measures for programs to fight HIV/AIDS, tuberculosis, and malaria
- Expanded reinforcement of key aspects of health systems and community-led response systems

C19RM should not support the procurement of vaccines, nor be primarily focused on vaccine deployment.

MPA

Update from the World Bank

COVID-19 vaccine financing

- The World Bank reached **\$2 billion** in approved financing for the purchase and distribution of COVID-19 vaccines for **17 developing countries**
- The \$2 billion funding is supporting COVID-19 vaccination in Afghanistan, Bangladesh, Cabo Verde, Cote d'Ivoire, Ecuador, El Salvador, Eswatini, Ethiopia, The Gambia, Honduras, Lebanon, Mongolia, Nepal, Philippines, Rwanda, Tajikistan, and Tunisia
- The Bank expects to support 50 countries with USD \$4 billion in financing for COVID-19 vaccines by mid-year
- On April 16, the World Bank Board aligned its eligibility criteria for COVID-19 vaccines with the revised eligibility criteria of COVAX and other multilateral partners

COVID-19 health response

- Within the initial World Bank Fast-Track COVID-19 Facility announced in April 2020, **86* projects** have now been approved, for a total of **USD \$4.2 billion**

**For clarity and alignment, this number no longer includes additional financing (AF) or standalone financing from the pandemic emergency financing facility (PEF)*



WORLD BANK GROUP

GFF

GFF C19 EHS Grants: Supporting ACT-A HSC While Delivering on GFF Mandate

Country Investment Case

(National priorities for advancing maternal, child, and adolescent health and nutrition outcomes)

COVID-19 Emergency Response Financing

GFF COVID-19 Essential Health Services (EHS) Grants

- Support countries to develop integrated country plans (C-19 and EHS)
- Leverage IDA for HSS and COVID-19 response and vaccine rollout
- Help remove system bottlenecks to facilitate delivery of COVID-19 tools
- Improve access to and use of essential health services
- Contribute to long term resilience of HS

Eligible Activities:

- Commodity Security & Supply Chain
- Infection Prevention and Control
- Community engagement incl BCC
- Private sector and CSO/ NGO engagement strategies
- Integrated Data sources, systems & processes
- Public Financial Management incl RMET
- Financial Barriers
- Health Systems Re-design

GFF C19EHS will not fund purchase of COVID vaccines

Grant Review Criteria

Context and Rationale	Country ownership Alignment with GFF Partner engagement
Technical Quality	<ul style="list-style-type: none"> • Coordination with national COVID-19 response coordinating bodies • In line with WHO SPRPs • Mitigate risks to EHS continuity • Improvements in HSD/HF beyond COVID-19 pandemic
Linkages to IDA	Will the grant leverage additional IDA or restructure IDA for EHS and ACT-A related support?
Rapid Roll Out	<ul style="list-style-type: none"> • Approval in FY2021 or the first quarter of FY2022 • Country capacity to disburse rapidly (target >60% disbursement within 24 months)